Patents by Inventor Kenji Morikami
Kenji Morikami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142119Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: July 8, 2022Publication date: May 11, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Publication number: 20220306578Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: April 29, 2020Publication date: September 29, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Publication number: 20200017442Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: January 4, 2019Publication date: January 16, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nabuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Publication number: 20190358205Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.Type: ApplicationFiled: July 19, 2019Publication date: November 28, 2019Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yoshito Nakanishi, Nukinori Akiyama, Kenji Morikami
-
Patent number: 10391081Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.Type: GrantFiled: December 26, 2014Date of Patent: August 27, 2019Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshito Nakanishi, Nukinori Akiyama, Kenji Morikami
-
Publication number: 20160340308Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: July 28, 2016Publication date: November 24, 2016Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo Kinoshita, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHll, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Publication number: 20160317499Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.Type: ApplicationFiled: December 26, 2014Publication date: November 3, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yoshito Nakanishi, Nukinori Akiyama, Kenji Morikami
-
Patent number: 9440922Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: GrantFiled: February 11, 2015Date of Patent: September 13, 2016Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Nobuya Ishii, Hiroshi Sakamoto, WooSang Hong, MinJeong Park, Yoshiyuki Ono, Yasuharu Kato, Kenji Morikami, Takashi Emura, Nobuhiro Oikawa
-
Patent number: 9126931Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: GrantFiled: June 9, 2010Date of Patent: September 8, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Nobuya Ishii, Hiroshi Sakamoto, WooSang Hong, MinJeong Park, Yoshiyuki Ono, Yasuharu Kato, Kenji Morikami, Takashi Emura, Nobuhiro Oikawa
-
Publication number: 20150150845Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: February 11, 2015Publication date: June 4, 2015Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Patent number: 8609656Abstract: The present invention provides a compound represented by the formula (1): wherein R1, R2 and R5 are each independently selected from a hydrogen atom, a halogen atom, a C1-C6 alkyl is substituted with a halogen atom and the like; R3 and R4 are each independently selected from a hydrogen atom, a halogen atom, a substituted C1-C6 alkyl group and the like; R6 and R7 are each independently selected from a hydrogen atom and a halogen atom; Z1 and Z2 are each independently selected from a hydrogen atom, a hydroxyl group and —O(CHR11)OC(?O)R12; Q is a group of the formula: (wherein G1 is C—Y2 or N; a ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle) a pharmaceutically acceptable salt thereof or a prodrug thereof.Type: GrantFiled: February 23, 2005Date of Patent: December 17, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuhiro Oikawa, Eisaku Mizuguchi, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi, Sawako Ozawa
-
Patent number: 8299252Abstract: It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.Type: GrantFiled: August 4, 2006Date of Patent: October 30, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, The University of TokyoInventors: Sawako Ozawa, Nobuhiro Oikawa, Eisaku Mizuguchi, Hirosato Ebiike, Fumio Watanabe, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi
-
Publication number: 20120083488Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: June 9, 2010Publication date: April 5, 2012Inventors: Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Nobuya Ishii, Hiroshi Sakamoto, WooSang Hong, MinJeong Park, Yoshiyuki Ono, Yashuharu Kato, Kenji Morikami, Takashi Emura, Nobuhiro Oikawa
-
Patent number: 8022205Abstract: A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].Type: GrantFiled: August 7, 2007Date of Patent: September 20, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuo Shimma, Hirosato Ebiike, Jun Ohwada, Hatsuo Kawada, Kenji Morikami, Mitsuaki Nakamura, Miyuki Yoshida, Nobuya Ishii, Masami Hasegawa, Shun Yamamoto, Kohei Koyama
-
Publication number: 20100168430Abstract: It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.Type: ApplicationFiled: August 4, 2006Publication date: July 1, 2010Applicants: Chugai Seiyaku Kabushiki Kaisha, The University of TokyoInventors: Sawako Ozawa, Nobuhiro Oikawa, Eisaku Mizuguchi, Hirosato Ebiike, Fumio Watanabe, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi, Yasuhiro Tamaki, Hidenori Takahashi
-
Publication number: 20100069629Abstract: A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].Type: ApplicationFiled: August 7, 2007Publication date: March 18, 2010Inventors: Nobuo Shimma, Hirosato Ebiike, Jun Ohwada, Hatsuo Kawada, Kenji Morikami, Mitsuaki Nakamura, Miyuki Yoshida, Nobuya Ishii, Masami Hasegawa, Shun Yamamoto, Kohei Koyama
-
Publication number: 20080119466Abstract: The present invention provides a compound represented by the formula (1): wherein R1, R2 and R5 are each independently selected from a hydrogen atom, a halogen atom, a C1-C6 alkyl is substituted with a halogen atom and the like; R3 and R4 are each independently selected from a hydrogen atom, a halogen atom, a substituted C1-C6 alkyl group and the like; R6 and R7 are each independently selected from a hydrogen atom and a halogen atom; Z1 and Z2 are each independently selected from a hydrogen atom, a hydroxyl group and —O(CHR11)OC(?O)R12; Q is a group of the formula: (wherein G1 is C—Y2 or N; a ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle) a pharmaceutically acceptable salt thereof or a prodrug thereof.Type: ApplicationFiled: February 23, 2005Publication date: May 22, 2008Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Nobuhiro Oikawa, Eisaku Mizuguchi, Kenji Morikami, Nobuo Shimma, Nobuya Ishii, Toshiyuki Tsukaguchi, Sawako Ozawa
-
Patent number: 4775084Abstract: An adhesive tape case provided with a cutter has a case body comprising two separable portions. The cutter is fixed adjacent to a tape outlet of the case body. In addition, two rollers for advancing a length of tape is provided adjacent to the tape outlet and driven through two gears. The gears are driven by the operation of an operational knob through a rack plate. The rack plate is adapted to engage with one of the gears when moving forward and to separate therefrom when moving backward. The operational knob is operated on the exterior of the case body or on the inside thereof, depending upon the size of the tape roll employed.Type: GrantFiled: December 29, 1986Date of Patent: October 4, 1988Assignee: Shachihata Industrial Co., Ltd.Inventors: Kenji Morikami, Hiroyasu Kato, Masaki Kida, Mituhiro Watabe